Microbot Medical has filed a notice of an exempt offering of securities to raise $7 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Microbot Medical is raising up to $7,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Microbot Medical
Microbot Medicals vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures within the human body, and offer physicians and their patients less invasive and more precise solutions. The companys innovations tap into one of the fastest-growing spaces in the medical field, the minimal invasive space. Microbot Medical develops micro-robotic medical devices that provide doctors and surgeons with new technological capabilities to improve a patients health, comfort and quality of life. Microbots current technological platforms, ViRob, TipCATand CardioSert, are comprised of highly advanced technologies from which the Company is currently developing its first product candidate: the Self-Cleaning Shunt, or SCS, for the treatment of hydrocephalus and normal pressure hydrocephalus.
To learn more about Microbot Medical, visit http://microbotmedical.com/
Microbot Medical Linkedin Page: https://www.linkedin.com/company/microbot-medical/
Contact:
Harel Gadot, President and Chief Executive Officer
718-875-3605
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.